Tissue Expansion in Breast Reconstruction Without Drains

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03784859
Collaborator
Sientra, Inc. (Industry)
5
1
19.2
0.3

Study Details

Study Description

Brief Summary

The primary objective of this small feasibility pilot study is to demonstrate that implant-based breast reconstruction (after treatment for cancer) can successfully be performed without prolonged drain placement, using a tissue expander with a reservoir and in-office transcutaneous fluid aspiration. Secondly, the investigators aim to provide enough confidence in this technique that a larger study can be performed to demonstrate fewer complications (infection, drain-related pain and re-operation rates) when compared to the use of conventional tissue expanders and/or implants with prolonged drain placement.

Condition or Disease Intervention/Treatment Phase
  • Device: Insertion of Tissue Expander with Fluid Reservoir

Detailed Description

Patients electing to have staged, implant-based, bilateral breast reconstruction at the time of mastectomy (for either cancer or cancer prevention) will undergo a standardized subpectoral tissue expander placement (using the Sientra AlloX2 dual-port device) on each side of the chest with a single piece of acellular dermal matrix (ADM). A single drain in the subcutaneous pocket of each breast will be used and removed on the first post-operative day. Patients will be admitted for overnight observation in the hospital. Each post-operative day fluid will be aspirated from each reservoir port using a standard sterile technique, and the volume recorded. After discharge, patients will be seen in the office within one week of discharge and fluid aspirated from each expander using the reservoir ports, and the volume shall be recorded. The aspiration will be repeated weekly until expansion is completed and/or the amount of fluid aspirated is less than 10 cc.

Patients will be asked to complete a 7 item multiple-choice questionnaire regarding their attitudes about their breast reconstruction, first at completion of tissue expansion and finally at their first follow-up visit following placement of permanent breast implants.

This study utilizes FDA 510k-classified devices that allow removal of fluid without drains, in lieu of more conventional expanders, allowing for the avoidance of prolonged drain usage.

Study Design

Study Type:
Observational
Actual Enrollment :
5 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Tissue Expansion in Breast Reconstruction Without Drains: A Study Using a Tissue Expander That Collects Periprosthetic Fluid
Actual Study Start Date :
Feb 25, 2019
Actual Primary Completion Date :
Jul 13, 2020
Actual Study Completion Date :
Oct 2, 2020

Arms and Interventions

Arm Intervention/Treatment
All patients in study

5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.

Device: Insertion of Tissue Expander with Fluid Reservoir
Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
Other Names:
  • Sientra AlloX2 Expander
  • Outcome Measures

    Primary Outcome Measures

    1. Number of patients with successful breast reconstruction using reservoir-expanders [4-6 months]

      The number of patients that successfully complete two stage implant-based breast reconstruction with fluid-reservoir tissue expanders and early drain removal. An outcome failure would be if the expander required removal due to uncontrolled seroma, infection or other factor that prevents a successful implant-based reconstruction.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients undergoing bilateral breast reconstruction following mastectomy (performed to treat stage I-III breast cancer or for prevention of breast cancer).

    • Non-smokers

    • BMI less than 31

    • No other significant surgical risk factors that make elective use of implants dangerous (e.g., presence of a pacemaker, frail health, dependence on blood thinners, uncontrolled diabetes, bleeding tendencies, autoimmune disorders, immune compromise)

    Exclusion Criteria:
    • Unilateral mastectomy patients

    • Current smokers

    • Those with bleeding dyscrasias or clotting disorders

    • Those who have had or will have a full axillary lymph node dissection

    • Cases where there is an unusually high degree of bleeding intra-operatively (more than 150 cc)

    • Those with a BMI greater than 30

    • Those with history of prior breast surgery (aside from lumpectomy or needle biopsy)

    • Those with a history of prior breast radiation

    • Those with stage IV or unresectable breast cancer

    • Significant surgical risk factors that make elective use of implants dangerous (e.g., presence of a pacemaker, frail health, dependence on blood thinners, uncontrolled diabetes, bleeding tendencies, autoimmune disorders, immune compromise)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars-Sinai Medical Center Los Angeles California United States 90048

    Sponsors and Collaborators

    • Cedars-Sinai Medical Center
    • Sientra, Inc.

    Investigators

    • Principal Investigator: Edward C Ray, MD, Cedars-Sinai Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Edward Ray, Staff Physician II, Cedars-Sinai Medical Center
    ClinicalTrials.gov Identifier:
    NCT03784859
    Other Study ID Numbers:
    • Pro00052823
    First Posted:
    Dec 24, 2018
    Last Update Posted:
    Oct 6, 2020
    Last Verified:
    Oct 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2020